TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06328582

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine rehabilitation training
Description: Balance function training: Patients were instructed to achieve weight shift between the left and right sides of the balance bar in a standing position.~Walking function training: based on hip, knee, and ankle control training, patients were instructed to take steps training.~Core muscle strength training: Patients were instructed to maintain 3 minutes of training in Bridge-style movement.~Functional training of daily living: including training on dressing and undressing, independent eating, painting, and writing.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Routine rehabilitation training
Description: Balance function training: Patients were instructed to achieve weight shift between the left and right sides of the balance bar in a standing position.~Walking function training: based on hip, knee, and ankle control training, patients were instructed to take steps training.~Core muscle strength training: Patients were instructed to maintain 3 minutes of training in Bridge-style movement.~Functional training of daily living: including training on dressing and undressing, independent eating, painting, and writing.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture Technique for Restoring Consciousness combined with Scalp Acupuncture
Description: Acupuncture Technique for Restoring Consciousness:~Main acupoints: Neiguan (bilateral), Renzhong, Sanyinjiao (affected side) Additional acupoints: Fengchi, Wangu, Yifeng (bilateral), and posterior pharyngeal wall needling.~Scalp Acupuncture Method:~Based on the standard treatment lines for scalp acupuncture \[17\], select the anterior oblique line of vertex-temporal region, posterior oblique line of vertex-temporal region, and anterior line of temporal region (bilateral).
Study: NCT05083143

Intervention type: BEHAVIORAL
Intervention: COVID-19 pandemic
Description: Patients diagnosed with testicular cancer in the urology clinic during and before the COVID-19 pandemic will be retrospectively evaluated and compared.

Intervention type: BEHAVIORAL
Intervention: COVID-19 pandemic
Description: Patients diagnosed with testicular cancer in the urology clinic during and before the COVID-19 pandemic will be retrospectively evaluated and compared.
Study: NCT05363709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balstilimab
Description: Given by Vein (IV)
Study: NCT06627309

Intervention type: DRUG
Intervention: Cyclophosphamide (CTX)
Description: Some patients may receive cyclophosphamide orally or intravenously at a dosage of 300 mg/m2 weekly.

Intervention type: DRUG
Intervention: Dara SC
Description: The treament follow the clinical routine practice, as daratumumab 16mg/kg iv qw OR dara SC 1800mg initially. The treatment schedule involve weekly administrations during cycles 1 to 2, following by biweekly administrations during cycles 3 to 6. Subsequently, monthly administrations are given as monotherapy.
Study: NCT06619808

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy
Description: Participants receive 20 session of hyperbaric oxygen therapy (HBOT) in one month (inhalation of 100% oxygen in a pressure chamber under 2.0 ATA for 60 minutes).
Study: NCT06622902

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: change flow from 6 to 2 LPM. Follow TcCO2 for 3 hours
Description: change flow from 6 to 2 LPM. Follow TcCO2 for 3 hours

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: change flow from 6 to 2 LPM. Follow TcCO2 for 3 hours
Description: change flow from 6 to 2 LPM. Follow TcCO2 for 3 hours

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: change flow from 2 to 6 LPM. Follow TcCO2 for 3h
Description: change flow from 2 to 6 LPM. Follow TcCO2 for 3h

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: change flow from 2 to 6 LPM. Follow TcCO2 for 3h
Description: change flow from 2 to 6 LPM. Follow TcCO2 for 3h
Study: NCT06447597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B007
Description: B007 high dose and low dose： Subcutaneous injection was administered on days 1 and 15

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: B007 matched Placebo Subcutaneous injection was administered on days 1 and 15
Study: NCT05250544

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control group
Description: For the adolescents in the control group; As soon as the process starts, the stopwatch will be started, and when the process is finished, it will be stopped. When the PCR Test starts, the crying state of the adolescent will be observed and recorded. After the procedure, the adolescent's fear (Childiren's Fear Scala (CFS)) and pain (Wong Baker FACES) related to the procedure will be evaluated separately by the adolescent, parent and observer and recorded in the form.
Study: NCT05690568

Intervention type: OTHER
Group type: OTHER
Intervention: multimodal chiropractic care
Description: functional movement score followed by intervention of multimodal chiropractic care including spinal/extremity manipulation and exercise recommendation
Study: NCT05301504

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1 biEBOV
Description: ChAdOx1 biEBOV is provided as a liquid in glass vials and administered intramuscularly into the deltoid of the non-dominant arm (preferably)
Study: NCT04936997

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-COV2 Pfizer Vaccine
Description: Vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Study: NCT05933096

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced multispectral optoacoustic tomography
Description: Ingestion of ICG-labeled food and 10 measurements with MSOT, 1 before ingestion of food, 8 afterwards, each after 60 minutes, 1 measurement 24 hours after ingestion

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced multispectral optoacoustic tomography
Description: Ingestion of ICG-labeled food and 10 measurements with MSOT, 1 before ingestion of food, 8 afterwards, each after 60 minutes, 1 measurement 24 hours after ingestion
Study: NCT05301504

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1 biEBOV
Description: ChAdOx1 biEBOV is provided as a liquid in glass vials and administered intramuscularly into the deltoid of the non-dominant arm (preferably)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1 biEBOV
Description: ChAdOx1 biEBOV is provided as a liquid in glass vials and administered intramuscularly into the deltoid of the non-dominant arm (preferably)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1 biEBOV
Description: ChAdOx1 biEBOV is provided as a liquid in glass vials and administered intramuscularly into the deltoid of the non-dominant arm (preferably)
Study: NCT06682689

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous vagus nerve stimulation
Description: Two groups will use a tVNS stimulator for 12 weeks. Group 1 will apply active stimulation for up to 4 hours daily at a comfortable level for 6 weeks, while Group 2 will use it at the lowest intensity (0.1 mA). After 6 weeks (T2), the groups will switch. Participants will be instructed to use the device for at least 1 hour a day, with a recommendation of 4 hours, following guidelines and recent studies. The CE-certified tVNS® E device non-invasively stimulates the vagus nerve via the ear. It is approved for treating a.o.depression. Device parameters (intensity, pulse length, frequency) mimic invasive VNS techniques, ensuring safe and effective signal transmission. Stimulation will be applied to the left ear, with intensity adjusted to a tingling sensation, avoiding discomfort. The study follows an approved protocol, with low-intensity stimulation as a control. The device delivers biphasic impulses at 25 Hz, with 28 seconds ON and 32 seconds OFF, and is safe for extended use.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcutaneous vagus nerve stimulation
Description: Two groups will use a tVNS stimulator for 12 weeks. Group 1 will apply active stimulation for up to 4 hours daily at a comfortable level for 6 weeks, while Group 2 will use it at the lowest intensity (0.1 mA). After 6 weeks (T2), the groups will switch. Participants will be instructed to use the device for at least 1 hour a day, with a recommendation of 4 hours, following guidelines and recent studies. The CE-certified tVNS® E device non-invasively stimulates the vagus nerve via the ear. It is approved for treating a.o.depression. Device parameters (intensity, pulse length, frequency) mimic invasive VNS techniques, ensuring safe and effective signal transmission. Stimulation will be applied to the left ear, with intensity adjusted to a tingling sensation, avoiding discomfort. The study follows an approved protocol, with low-intensity stimulation as a control. The device delivers biphasic impulses at 25 Hz, with 28 seconds ON and 32 seconds OFF, and is safe for extended use.
Study: NCT06682195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy combined with Toripalimab
Description: 1, Neoadjuvant Chemotherapy Phase Combined with Toripalimab~1. First Phase of Neoadjuvant Chemotherapy: Epirubicin + Cyclophosphamide + Toripalimab. Administered intravenously: 100 mg/m² Epirubicin + 600 mg/m² Cyclophosphamide + 240 mg Toripalimab, every 3 weeks for a total of 6 weeks.~2. Second Phase of Neoadjuvant Chemotherapy: Albumin-bound Paclitaxel + Toripalimab. Administered intravenously: 260 mg/m² Albumin-bound Paclitaxel + 240 mg Toripalimab, every 3 weeks for a total of 6 weeks.~2, Receive Breast Cancer Radical Surgery After 4 Cycles of Neoadjuvant Chemotherapy 3, Postoperative Adjuvant Therapy~1. If pathology indicates pCR: Continue immunotherapy, administering 240 mg Toripalimab intravenously every 3 weeks for a total of 1 year.~2. If pathology indicates non-PCR: Continue postoperative adjuvant chemotherapy combined with Toripalimab.~4, Perform Gene Testing on Biopsy Tissue Before Treatment, and Collect Blood Samples for ctDNA Testing Before and After Treatment.
Study: NCT06684834

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5:2 carbohydrate restriction
Description: Carbohydrate ingestion restricted to \<8% of energy intake on 2 self-selected consecutive days each week over 28-30 days. Ad libitum dietary amount, type and pattern followed on the remaining 5 days each week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early time-restricted carbohydrate intake
Description: Carbohydrate intake restricted to \<8% of energy intake after 4pm each day for 28 days. Ad libitum dietary amount, type and pattern followed before 4pm.
Study: NCT06685575

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Foraminotomy Surgery
Description: Endoscopic Foraminotomy Surgery in Stable Lumbar Foraminal Stenosis
Study: NCT06685471

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Screeing test
Description: Simulation-Based Training Program Effect on Pediatric Nurses' Knowledge and Performance Regarding Heel-Prick during Newborn Blood Screening Test
Study: NCT06684236

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: transcutaneous electrical stimulation
Description: electrical stimulation is given through electrodes attached to the skin

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electrodes attachment
Description: electrodes are attached to the skin area of Neiguan acupoint, which is located on 3cm above the transverse crease of the wrist

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: electrodes attachment
Description: electrodes are attached to the skin area of Neiguan acupoint, which is located on 3cm above the transverse crease of the wrist
Study: NCT05498155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Olaparib monotherapy group
Description: Neoadjuvant olaparib monotherapy (300 mg BID) for four to six 28-day cycles.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Neoadjuvant combination therapy with olaparib plus durvalumab
Description: Neoadjuvant combination therapy with olaparib (300 mg BID) plus durvalumab (1500 mg IV Q4W) for four to six 28-day cycles.
Study: NCT06682364

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Trauma-informed case management for women who use drugs
Description: This intervention assesses the adequacy in which components of the gender-specific and trauma-informed intervention function together using a sample of 50 community-recruited CJI women who use opioids illicitly.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma-informed case management for women who use drugs
Description: This intervention assesses the adequacy in which components of the gender-specific and trauma-informed intervention function together using a sample of 50 community-recruited CJI women who use opioids illicitly.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CRS Only Intervention
Description: This intervention assesses the adequacy in which components of the gender-specific case management by certified peer recovery specialists function together using a sample of 50 community-recruited CJI women who use opioids illicitly.
Study: NCT06685666

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional warm-up method specific to handball
Description: The traditional warm-up program specific to handball consists of 6 basic sections: static stretching, aerobic work, dynamic mobility exercises, passes and crosses, shooting on goal and shooting according to position, and lasts 17 minutes in total.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: elastic band exercises added to the traditional warm-up
Description: The experimental group will be given elastic band exercises for 6 weeks after the static and dynamic exercises in the traditional warm-up and then continue with the warm-up with the ball. The exercise program was planned progressively. The exercises will be done in the first 3 weeks, 2 sets of 10 repetitions with a light resistance band. Then the exercises will be done in 3 sets of 10 repetitions with a medium resistance band. There are 8 band exercises in total.This exercise; Flexion and Extension Exercise in Diagonal Pattern, Internal and external rotation with the arm next to the body and the elbow in 90 degrees flexion, Internal and external rotation with the arm in 90 degrees abduction and the elbow in 90 degrees flexion, Scaption Exercise, Rowing, Biceps and Triceps (elbow flexion and extansion exercise), Wrist Flexors and Extensors (wrist flexion and extansion exercise).
Study: NCT05733702

Intervention type: OTHER
Intervention: All participants will be asked to provide data and samples for collection and analysis.
Description: During the first year from the date of inclusion, data related to demographics, lifestyle, laboratory and physical examinations will be collected at baseline, at 3 months, and at 12 months. Patient-Reported Outcomes (PROs) with voice recordings will be collected at different time points in-between clinical visits using the Colive application. Participants will be asked to provide biological samples (i.e., blood, dried blood spots and stool are mandatory; saliva, urine and hair are optional), tissue samples from endoscopic biopsy and imaging data (if performed as per standard of care) at three timepoints (baseline; 3 months; 12 months). One unscheduled visit may be included in the study in case of occurrence of flare or treatment change.A long-term follow-up (starting from month 12 and up to 4 years after month 12) will include the collection of medical data on a yearly basis, collection of PROs with voice recording every 6 months and continuous collection of data using the smartwatch.
Study: NCT05935644

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ORCHID
Description: The intervention includes 8 modules, which are delivered online, approximately 30 minutes per session, and participants will engage a minimum of once per week. Participants may also meet online or in-person with a navigator, up to 4 times.
Study: NCT04655092

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: P1101 (Ropeginterferon alfa-2b)
Description: The subjects who have completed the 52-week treatment duration in Study A19-201 will be treated with P1101, starting at the dose at Week 50. The dose during this study may be increased or decreased up to 500 μg depending on the condition. This study will be continued as a post-marketing clinical study after acquisition of the marketing approval of P1101.
Study: NCT05578716

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Partially hydrolysed formula
Description: Partially hydrolysed formula

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Partially hydrolysed formula
Description: Partially hydrolysed formula
Study: NCT05287308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: doxorubicin 50\~60mg/m2, i.v., d1, q3w or q2w.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin
Description: doxorubicin 50\~60mg/m2, i.v., d1, q3w or q2w.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin
Description: epirubicin 80\~100mg/m2, i.v., d1, q3w or q2w.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epirubicin
Description: epirubicin 80\~100mg/m2, i.v., d1, q3w or q2w.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pirarubicin
Description: pirarubicin 40\~50mg/m2, i.v., d1, q3w or q2w.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pirarubicin
Description: pirarubicin 40\~50mg/m2, i.v., d1, q3w or q2w.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: cyclophosphamide 600mg/m2, i.v., d1, q3w or q2w.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: cyclophosphamide 600mg/m2, i.v., d1, q3w or q2w.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albumin-bound paclitaxel
Description: albumin-bound paclitaxel 260mg/m2, i.v., d1, q3w; 260mg/m2, i.v., d1, q2w; or 125mg/m2, i.v., d1, qw.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: paclitaxel 175mg/m2, i.v., d1, q3w; 175mg/m2, i.v., d1, q2w; or 80mg/m2, i.v., d1, qw.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: docetaxel 80\~100mg/m2, i.v., d1, q3w.
Study: NCT05347901

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography, Genomics NGS sequencing
Description: The inner diameter of left main coronary artery, anterior descending branch, circumflex branch and right coronary artery was measured by echocardiography. Blood samples were send for genomics NGS sequencing
Study: NCT05483686

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shine
Description: This tailored, multifaceted mobile intervention aims to improve HIV-related outcomes and increase gender affirmation among African American transgender women. Potential users will opt-in by texting from their own mobile phone and, once registered, will be enrolled into a program that will be theory-based, targeted, tailored, and personalized. Users will receive three main types of texts: informational, motivational, and skill-building. Finally, the program will include three web-based video components: scripted vignettes, unscripted peer narratives, and educational instruction. By developing an intervention using a technology that is part of the everyday lives of most African Americans, the aim is to reduce HIV disparities. The proposed intervention can be used by clinics and community-based organizations that serve transgender women.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: A playlist of CDC-developed videos designed to provide information on HIV for transgender women
Study: NCT02229175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: intravitreal injections of antibodies inhibiting vascular endothelial growth factor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab
Description: intravitreal injections of antibodies inhibiting vascular endothelial growth factor

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PASCAL Endpoint Management (EpM) laser treatment
Description: This is an algorithm that is included in the PASCAL 577 mm yellow laser system (Topcon, Santa Clara, CA). This is FDA-approved for treatment of diabetic retinopathy and diabetic macular edema.
Study: NCT05847738

Intervention type: BEHAVIORAL
Intervention: Pain assessment
Description: Pain was assesd postoperatively in both groups at time intervals
Study: NCT05933096

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced multispectral optoacoustic tomography
Description: Ingestion of ICG-labeled food and 10 measurements with MSOT, 1 before ingestion of food, 8 afterwards, each after 60 minutes, 1 measurement 24 hours after ingestion
Study: NCT05204862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TU2218
Description: orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TU2218
Description: orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TU2218
Description: orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TU2218
Description: orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TU2218
Description: orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 antibody
Description: Intravenously administered
Study: NCT05358678

Intervention type: DIAGNOSTIC_TEST
Intervention: cs niche group
Description: A niche is formally defined by the European Niche Taskforce as an indentation of the uterine myometrium of at least 2 mm at the site of the CS scars. A niche can be sub classified as follows:~1. Simple niche~2. Simple niche with one branch~3. Complex niche (with more than one branch).~The following measurements will be taken:~* Length.~* Depth.~* Width.~* RMT (residual myometrium thickness).~* AMT (adjacent myometrium thickness).~* Distance between the niche and the VV (vesico-vaginal) fold.~* Distance between the niche and the external os. We will also comment on the position of the uterus (AVF or RVF), presence or absence of intra cavitary fluid and its thickness.